GW 471558
Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mycoses; Pneumocystis pneumonia
Most Recent Events
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 26 Sep 2000 Preclinical development for Mycoses in Spain (Unknown route)
- 26 Sep 2000 Preclinical development for Pneumocystis pneumonia in Spain (Unknown route)